MétaCan
Menu
Back to cohort
Record W4307092553 · doi:10.1093/ecco-jcc/jjac160

Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis

2022· review· en· W4307092553 on OpenAlexaff
Tanmay Sharma, Christopher Ma, Rocío Sedaño, Jurij Hanžel, Cassandra McDonald, Malcolm Hogan, Gursimran Kochhar, Neeraj Narula, Laurent Peyrin‐Biroulet, Silvio Danese, John K MacDonald, Vipul Jairath

Bibliographic record

VenueJournal of Crohn s and Colitis · 2022
Typereview
Languageen
FieldMedicine
TopicAnorectal Disease Treatments and Outcomes
Canadian institutionsMcMaster UniversityLondon Health Sciences CentreUniversity of CalgaryUniversity of WindsorWestern University
Fundersnot available
KeywordsPlaceboMedicineMeta-analysisInternal medicineClinical trialRandomized controlled trialConfidence intervalCrohn's diseaseDiseaseSurgeryPathologyAlternative medicine

Abstract

fetched live from OpenAlex

BACKGROUND AND AIMS: Perianal fistulizing disease is a common complication of Crohn's disease [CD], for which new therapies are urgently needed. To assist the design of clinical trials for novel therapeutics, we conducted a systematic review and meta-analysis of randomised controlled trials [RCTs] to quantify placebo rates and identify factors influencing them in perianal CD [pCD]. METHODS: We searched MEDLINE, Embase and CENTRAL from inception to June 2021. Eligible studies were placebo-controlled trials of pharmacological interventions for pCD. Placebo fistula response and remission rates for induction and maintenance trials were extracted and pooled using a random-effects model. Mixed-effects meta-regression was used to evaluate the impact of patient and study-level characteristics on point estimates. RESULTS: In 17 RCTs [13 induction, five maintenance] the pooled placebo fistula response and remission rate for induction trials was 25% (95% confidence interval [CI] 17-36%) and 17% [95% CI 11-25%], respectively. For maintenance trials, the pooled placebo fistula response and remission rate was 23% [95% CI 17-32%] and 19% [95% CI 14-25%], respectively. Trials enrolling patients with less disease activity and a higher proportion with ileal predominant disease were associated with significantly higher placebo response rates. Trials originating in Europe [compared to North America], therapies requiring perianal injection and a longer timepoint to measure remission were associated with higher placebo remission rates. CONCLUSIONS: Placebo response and remission rates in pCD trials are influenced by patient and disease-related factors, as well as the type of intervention being studied. These contemporary rates will inform trial design for novel therapeutics.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.077
metaresearch head score (Gemma)0.160
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.077
Threshold uncertainty score0.408

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0770.160
Meta-epidemiology (narrow)0.0040.003
Meta-epidemiology (broad)0.0310.063
Bibliometrics0.0100.009
Science and technology studies0.0010.002
Scholarly communication0.0050.004
Open science0.0030.002
Research integrity0.0040.003
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.106
GPT teacher head0.410
Teacher spread0.304 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicAnorectal Disease Treatments and OutcomesFrench-language works237,207